Get the Stockscreener App
10.92
6.12%
0.63
After Hours:
10.86
-0.06
-0.55%
Arvinas Inc stock is traded at $10.92, with a volume of 547.47K.
It is up +6.12% in the last 24 hours and down -17.86% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$10.29
Open:
$10.54
24h Volume:
547.47K
Relative Volume:
0.67
Market Cap:
$698.45M
Revenue:
$262.60M
Net Income/Loss:
$-80.80M
P/E Ratio:
-8.9795
EPS:
-1.2161
Net Cash Flow:
$-275.70M
1W Performance:
+0.28%
1M Performance:
-17.86%
6M Performance:
+40.90%
1Y Performance:
+34.32%
1-Day Range:
$10.39
$11.00
1-Week Range:
$9.9628
$11.25
52-Week Range:
$5.90
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
10.92 | 658.16M | 262.60M | -80.80M | -275.70M | -1.2161 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Hold" from Analysts - MarketBeat
Aug EndMonth: Is Arvinas Inc in a bullish channelMarket Growth Review & Weekly Breakout Watchlists - baoquankhu1.vn
ARVN PE Ratio & Valuation, Is ARVN Overvalued - Intellectia AI
H.C. Wainwright reiterates Arvinas stock rating on trial data - Investing.com UK
H.C. Wainwright reiterates Arvinas stock rating on trial data By Investing.com - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX) - The Globe and Mail
Arvinas’ chief medical officer Berkowitz sells $71k in shares By Investing.com - Investing.com South Africa
Noah Berkowitz Sells 6,435 Shares of Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas’ chief medical officer Berkowitz sells $71k in shares - Investing.com UK
Arvinas (ARVN) CMO reports automatic RSU tax-withholding share sale - Stock Titan
Tranche Update on Arvinas, Inc.'s Equity Buyback Plan announced on September 17, 2025. - marketscreener.com
Arvinas (ARVN): Citigroup Raises Price Target to $21.00 and Main - GuruFocus
Arvinas (NASDAQ:ARVN) Price Target Raised to $21.00 at Citigroup - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Arvinas (NASDAQ:ARVN) Stock Price Expected to Rise, BTIG Research Analyst Says - MarketBeat
BTIG Analyst Raises Price Target for Arvinas (ARVN) to $16 | ARV - GuruFocus
Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
ARVN Should I Buy - Intellectia AI
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 By Investing.com - Investing.com South Africa
Arvinas reports positive Phase 1 data for Parkinson’s drug ARV-102 - Investing.com India
BTIG raises Arvinas stock price target on positive trial data By Investing.com - Investing.com Australia
Arvinas, Inc. (ARVN) reports Q4 loss, misses revenue estimates - MSN
BTIG raises Arvinas stock price target on positive trial data - Investing.com
ARV-102 Data Strengthens Neurodegeneration Pipeline Prospects, Supporting Higher $16 Target and Buy Rating on Arvinas - TipRanks
Arvinas (ARVN) Reports Promising Phase 1 Trial Results for ARV-102 in Parkinson's Disease - GuruFocus
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data By Investing.com - Investing.com Australia
Arvinas, Inc. Reports Forward-Looking Statements and Updates on ARV-102 Neurodegenerative Disease Program – March 2026 - Minichart
Truist reiterates Hold on Arvinas stock after Parkinson’s trial data - Investing.com
Arvinas (NASDAQ:ARVN) Trading Down 7.8%What's Next? - MarketBeat
Arvinas Reports Positive Phase 1 Data for ARV-102 - TipRanks
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days - The Manila Times
Arvinas (ARVN) reports positive Phase 1 ARV-102 data in Parkinson’s disease - Stock Titan
Experimental Parkinson’s pill from Arvinas cuts key brain protein by 50% - Stock Titan
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days - Bitget
Arvinas shows market leadership with jump to 92 RS rating - MSN
Arvinas (ARVN) settles 6,022 RSUs; insider sold 5,685 shares - Stock Titan
ARVN SEC FilingsArvinas 10-K, 10-Q, 8-K Forms - Stock Titan
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas calls for new approaches in neurodegenerative disease research - Traders Union
Goldman Sachs Downgrades Arvinas (ARVN) - MSN
Investor Mood: Can Arvinas Inc outperform in the next rally2026 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Arvinas, Inc. (ARVN) Reports Q2 Loss, Misses Revenue Estimates - MSN
Arvinas (ARVN) corrects CEO equity grant to 147,179 RSUs in Form 4/A - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 7.8%What's Next? - MarketBeat
Arvinas to present ARV-102 Parkinson’s trial data at conference By Investing.com - Investing.com South Africa
Arvinas, Inc. (NASDAQ:ARVN) Q4 2025 earnings call transcript - MSN
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - The Manila Times
Arvinas, Inc. to Present Phase 1 Trial Data on ARV-102 for Parkinson’s Disease at AD/PD 2026 Conference - Quiver Quantitative
Arvinas to present ARV-102 Parkinson’s trial data at conference - Investing.com
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 - GlobeNewswire
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):